Isec Healthcare Ltd · SGX:40T
Isec Healthcare — Q1 2019 Earnings Presentation
20 slides from Isec Healthcare's earnings presentation, May 2019
Slide 1: Corporate Presentation
LOCAL FOCUS REGIONAL VISION Corporate Presentation 3 months ended 31 March 2019 Page 0
Slide 2: reviewed by the Company’s sponsor, (the “Sponsor”), for compliance with the Limited (the “SGX-ST”)
This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist
Slide 3: Table of Content
Table of Content Business Overview Competitive Strengths of the Group Business Strategy and Expansion Plans Corporate Developments and Use of Proceeds 3 months Financial Highlights for the Period Ended 31 March 2019 Page 2
Slide 4: Business Overview
Business Overview Page 3
Slide 5: Business Overview
Business Overview • Specialised Health Services – Medical eye care service provider • ISEC is a comprehensive medical eye care service provider, with ambulatory surgical centres in Malaysia (Kuala Lumpur, Penang, Malacca & Sibu) and provides specialist medical ophthalmology services to Lee Hung Ming
Slide 6: Competitive Strengths of the Group
Competitive Strengths of the Group Page 5
Slide 7: Competitive Strengths of the Group
Business Overview Competitive Strengths of the Group 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well pos
Slide 8: Business Strategy And Expansion Plan
Business Strategy And Expansion Plan Page 7
Slide 9: Our Business Strategies
Our Business Strategies ◼ To reach out to more patients in locations where we currently operate, as well as new locations such as major Growing the ISEC cities or locations in Peninsular Malaysia, East Malaysia and Brand and Singapore Expanding into ◼ To expand via setting up of subsidiaries, joint
Slide 10: Expansion Plans: Business expansion in the Asia Pacific
Expansion Plans Business expansion in the Asia Pacific region (including Malaysia Malaysia & and Singapore) Singapore Target Countries Page 9
Slide 11: Corporate Developments And Use of Proceeds
Corporate Developments And Use of Proceeds Page 10
Slide 12: Corporate Developments
Corporate Developments COMPLETED ACQUISITION OF THE REMAINING 49% OF THE ENTIRE ISSUED AND PAID-UP SHARE CAPITAL OF ISEC (PENANG) SDN. BHD. (“ISEC PENANG”) Following the completion of the above acquisition on 23 April 2019, the interest of ISEC Sdn. Bhd., wholly-owned subsidiary of the Company, in t
Slide 13: Use of Proceeds
Use of Proceeds As at 9 May 2019 Amount allocated pursuant to reallocation of Use of proceeds Amount allocated unutilised listing Amount S$’000 expenses utilised Balance S$’000 S$’000 S$’000 Business expansion in Asia Pacific region (including Malaysia and 13,800 300 (13,316) (N1) 784 Singapore) Gen
Slide 14: 3 Months Financial Highlights
3 Months Financial Highlights for the Period Ended 31 March 2019 Page 13
Slide 15: Revenue
Revenue SGD’mil 12.0 10.0 9.6 9.9 8.0 7.3 7.2 6.0 4.0 2.4 2.6 2.0 - 3M2018 3M2019 Malaysia Singapore Group ◼ 3M2019 vs 3M2018 The increase in Group revenue was mainly attributable to increased business activities from the Group’s specialised health services in both Malaysia and Singapore. Page 14
Slide 16: Revenue – Malaysia
Revenue – Malaysia RM’mil SGD’mil 1.4% 25.0 2.3% 8.0 21.6 22.1 7.2 7.3 7.0 20.0 6.0 15.0 5.0 4.0 10.0 3.0 2.0 5.0 1.0 - - 3M2018 3M2019 3M2018 3M2019 ◼ Revenue from Malaysia operations in Ringgit Malaysia (“RM”) increased from RM21.6 million in 3M2018 to RM22.1 million in 3M2019, up 2.3% mainly due
Slide 17: EBITDA and Profit After Tax (PAT)
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) and Profit After Tax (PAT) SGD’000 17.6% 4,000 3,678 3,500 3,128 3.5% 3,000 2,500 2,221 2,145 2,000 1,500 1,000 500 - EBITDA PAT 3M2018 3M2019 ◼ EBITDA was S$3.7 million in 3M2019 as compared to S$3.1 million in 3M2018. ◼ PAT was
Slide 18: Cash Position
Cash Position 28.6 Total cash and cash equivalents 27.1 Unutilised IPO proceeds 0.9 1.1 Cash balances 27.7 26.0 - 5.0 10.0 15.0 20.0 25.0 30.0 As at 31 Mar 2019 As at 31 Dec 2018 SGD’mil ◼ Total cash and cash equivalents as at 31 March 2019 was S$28.6 million. No bank borrowings. ◼ Cash balances (ex
Slide 19: Statement of Financial Position
Statement of Financial Position S$’000 31 March 31 December 2019 2018 Key Assets Plant and equipment 3,686 3,735 Right-of-use assets 4,902# - Intangible assets 38,117^ 38,182^ Trade and other receivables 3,380 2,984 Cash and cash equivalents 28,599 27,105 Key Liabilities Lease liabilities – non-curr
Slide 20: Thank You
Thank You Page 19